Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: United Therapeutics Corporation, 3 years.
United Therapeutics Corporation
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 9, 2026 | United Therapeutics Corporation | Option exercise | +1,310 | — | — |
| Jul 25, 2025 | United Therapeutics Corporation | Option exercise | +1,190 | — | — |
| Jun 24, 2025 | United Therapeutics Corporation | Option exercise | +5,000 | $175.43 | $877,150 |
| Jun 24, 2025 | United Therapeutics Corporation | Open-market sale | −3,036 | $289.60 | $879,226 |
| Nov 5, 2024 | United Therapeutics Corporation | Option exercise | +10,000 | $175.43 | $1,754,300 |
| Nov 5, 2024 | United Therapeutics Corporation | Open-market sale | −8,571 | $381.61 | $3,270,779 |
| Nov 5, 2024 | United Therapeutics Corporation | Open-market sale | −1,429 | $382.28 | $546,278 |
| Jul 13, 2024 | United Therapeutics Corporation | Option exercise | +1,800 | — | — |
| Mar 6, 2024 | United Therapeutics Corporation | Option exercise | +10,000 | $88.03 | $880,300 |
| Mar 6, 2024 | United Therapeutics Corporation | Sold back to the company | −10,000 | $236.97 | $2,369,700 |
| Dec 1, 2023 | United Therapeutics Corporation | Option exercise | +5,000 | $88.03 | $440,150 |
| Dec 1, 2023 | United Therapeutics Corporation | Sold back to the company | −5,000 | $240.73 | $1,203,650 |
| Jul 7, 2023 | United Therapeutics Corporation | Option exercise | +1,750 | — | — |
| May 22, 2023 | United Therapeutics Corporation | Option exercise | +5,000 | $63.90 | $319,500 |
| May 22, 2023 | United Therapeutics Corporation | Sold back to the company | −5,000 | $218.59 | $1,092,950 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.